These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 7875951)
21. Assessing the role of drugs in suicidal ideation and suicidality. Reith DM; Edmonds L CNS Drugs; 2007; 21(6):463-72. PubMed ID: 17521226 [TBL] [Abstract][Full Text] [Related]
22. Suicide prevention and serotonergic drugs. Montgomery SA Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():83-5. PubMed ID: 8201249 [TBL] [Abstract][Full Text] [Related]
23. Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. Hansen L J Psychopharmacol; 2003 Dec; 17(4):451-2. PubMed ID: 14870959 [TBL] [Abstract][Full Text] [Related]
25. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Möller HJ Eur Arch Psychiatry Clin Neurosci; 2006 Dec; 256(8):476-96. PubMed ID: 17143567 [TBL] [Abstract][Full Text] [Related]
26. Use of selective serotonin reuptake inhibitors in children and adolescents. Wong IC; Besag FM; Santosh PJ; Murray ML Drug Saf; 2004; 27(13):991-1000. PubMed ID: 15471506 [TBL] [Abstract][Full Text] [Related]
27. An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine. Amitai M; Taler M; Lebow M; Ben-Baruch R; Apter A; Fennig S; Weizman A; Chen A Eur Neuropsychopharmacol; 2020 Nov; 40():61-69. PubMed ID: 32747326 [TBL] [Abstract][Full Text] [Related]
28. Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Gartside SE; Leitch MM; Young AH Neuropsychopharmacology; 2003 Sep; 28(9):1572-8. PubMed ID: 12784107 [TBL] [Abstract][Full Text] [Related]
29. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Andrews JM; Ninan PT; Nemeroff CB Depression; 1996; 4(2):48-56. PubMed ID: 9160640 [TBL] [Abstract][Full Text] [Related]
30. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? Cain JW J Clin Psychiatry; 1992 Aug; 53(8):272-7. PubMed ID: 1500403 [TBL] [Abstract][Full Text] [Related]
35. Newer generation antidepressants for depressive disorders in children and adolescents. Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227 [TBL] [Abstract][Full Text] [Related]
36. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Tauscher-Wisniewski S; Disch D; Plewes J; Ball S; Beasley CM Psychol Med; 2007 Nov; 37(11):1585-93. PubMed ID: 17640442 [TBL] [Abstract][Full Text] [Related]
37. Controversies in the Pharmacotherapy of Adolescent Depression. Masi G Curr Pharm Des; 2022; 28(24):1975-1984. PubMed ID: 35619257 [TBL] [Abstract][Full Text] [Related]
38. The neurobiology of suicide risk: a review for the clinician. Mann JJ; Oquendo M; Underwood MD; Arango V J Clin Psychiatry; 1999; 60 Suppl 2():7-11; discussion 18-20, 113-6. PubMed ID: 10073382 [TBL] [Abstract][Full Text] [Related]